KaydedilenlerDerginizi ekleyin

Dergiler / art / 2017 / Cilt: 32 - Sayı: 4

Up-Regulated Complement 3 Production by Toll-Like Receptor 9/Transforming Growth Factor-Beta 1/Complement 3 Pathway in Whole Blood Cells of Lupus Thrombocytopenia

Yi YUAN
Ling ZHAO
Ning MA
Zhuang YE
Zhenyu JIANG
Congqiu CHU
Dergi
art
Sayfa
275–283
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus TLR9/TGF-?1/C3 pathway might be in operation mediating lupus thrombocytopenia.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to assess the complement 3 (C3) expressions in whole blood cells and verify a pathway toll-like receptor 9 (TLR9)/transforming growth factor-beta 1 (TGF-?1)/C3 for C3 regulation in mediating thrombocytopenia (TCP) in patients with systemic lupus erythematosus (SLE).Patients and methods: The study included 63 newly diagnosed SLE patients (2 males, 61 females; mean age 39.5 years; range 15 to 67 years).
📊
Temel Bulgular & Veri:Whole blood messenger ribonucleic acid expression for C3, TLR9 and TGF-?1 were measured by quantitative reverse transcription real-time polymerase chain reaction in SLE patients with TCP (n=38) and age- and sex-matched SLE patients without TCP (n=25) at baseline and in 10 SLE patients with TCP after four weeks of treatment.
💡
Sonuç & Katkı:Thus TLR9/TGF-?1/C3 pathway might be in operation mediating lupus thrombocytopenia.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This study aims to assess the complement 3 (C3) expressions in whole blood cells and verify a pathway toll-like receptor 9 (TLR9)/transforming growth factor-beta 1 (TGF-?1)/C3 for C3 regulation in mediating thrombocytopenia (TCP) in patients with systemic lupus erythematosus (SLE).Patients and methods: The study included 63 newly diagnosed SLE patients (2 males, 61 females; mean age 39.5 years; range 15 to 67 years). Whole blood messenger ribonucleic acid expression for C3, TLR9 and TGF-?1 were measured by quantitative reverse transcription real-time polymerase chain reaction in SLE patients with TCP (n=38) and age- and sex-matched SLE patients without TCP (n=25) at baseline and in 10 SLE patients with TCP after four weeks of treatment. Whole blood cells from SLE patients with TCP were cultured in the presence of TLR9 ligand cytosine-phosphateguanine, recombinant human TGF-?1, TGF-? receptor inhibitor/activin receptor-like kinase inhibitor SB431542. TGF-?1 and C3 levels in whole blood cells cultures were determined by quantitative reverse transcription real-time polymerase chain reaction and enzyme-linked immunosorbent assay.Results: Whole blood cells from SLE patients with TCP displayed an enhanced gene expression for C3, TLR9 and TGF-?1 compared with that of SLE patients without TCP (p<0.01 for C3, p<0.05 for TLR9 and TGF-?1). SLE patients with TCP had decreased plasma levels of C3 suggesting excessive consumption. In whole blood cell culture, engagement of TLR9 led to the increased gene expression of C3. Furthermore, TGF-?1 inhibitor abolished TLR9 stimulation on C3 gene expression.Conclusion: These results suggest that blood cells are the source of extra-hepatic synthesis of C3 in SLE patients with TCP and this synthesis of C3 was up-regulated by TLR9 via induction of TGF-?1. Thus TLR9/TGF-?1/C3 pathway might be in operation mediating lupus thrombocytopenia.

🔖

Bu Makaleye Atıf Yap

YUAN, Y., ZHAO, L., MA, N., YE, Z., JIANG, Z., CHU, C. (2017). Up-Regulated Complement 3 Production by Toll-Like Receptor 9/Transforming Growth Factor-Beta 1/Complement 3 Pathway in Whole Blood Cells of Lupus Thrombocytopenia. art, Cilt: 32 - Sayı: 4, 275–283. https://ajindex.com/articles/351674

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Naughton MA, Botto M, Carter MJ, Alexander GJ, Goldman JM, Walport MJ. Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 1996;156:3051-6
  2. Reis ES, Barbuto JA, Isaac L. Human monocytederived dendritic cells are a source of several complement proteins. Inflamm Res 2006;55:179-84
  3. Passwell J, Schreiner GF, Nonaka M, Beuscher HU, Colten HR. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 1988;82:1676-84
  4. Falus A. Regulation of complement biosynthesis by tissue-specific and hormonal factors. Immunol Lett 1990;24:227-30
  5. Falus A, Beuscher HU, Auerbach HS, Colten HR. Constitutive and IL 1-regulated murine complement gene expression is strain and tissue specific. J Immunol 1987;138:856-60
  6. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366-9
  7. Ktona E, Barbullushi M, Backa T, Idrizi A, Shpata V, Roshi E. Evaluation of thrombocytopenia in systemic lupus erythematosus and correlation with different organs damages. Mater Sociomed 2014;26:122-4
  8. Ziakas PD, Poulou LS, Giannouli S, Tzioufas AG, Voulgarelis M. Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse. Ann Rheum Dis 2007;66:130-1
  9. Ghaly NR, Kotb NA, Nagy HM, Rageh el SM. Toll-like receptor 9 in systemic lupus erythematosus, impact on glucocorticoid treatment. J Dermatolog Treat 2013;24:411-7
  10. Qin M, Li Y, Yang X, Wu H. Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis. Immunopharmacol Immunotoxicol 2014;36:251-60
  11. Chow EK, O'connell RM, Schilling S, Wang XF, Fu XY, Cheng G. TLR agonists regulate PDGF-B production and cell proliferation through TGF-beta/ type I IFN crosstalk. EMBO J 2005;24:4071-81
  12. Høgåsen AK, Hestdal K, Høgåsen K, Abrahamsen TG. Transforming growth factor beta modulates C3 and factor B biosynthesis and complement receptor 3 expression in cultured human monocytes. J Leukoc Biol 1995;57:287-96
  13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
  14. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012;38:454-62
  15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease ac